Study of INT-747 in Patients With Diabetes and Presumed NAFLD

NCT00501592 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type II
Fatty Liver

Interventions

DRUG: INT-747
DRUG: Placebo

Sponsor

Intercept Pharmaceuticals